Sana Biotechnology is under investigation by Pomerantz LLP following the company's announcement that it would suspend development of its SC291 oncology program and SC379 glial progenitor cell program. The investigation focuses on potential securities fraud and unlawful business practices that may have negatively impacted the company's investors.
The decision to suspend the programs was revealed in a press release on November 4, 2024, where Sana's President and CEO, Steve Harr, stated the company would focus investments on areas with the "greatest impact for patients." This strategic shift also involved workforce reductions to reduce cash burn.
The market reacted swiftly to the news, with Sana's stock price plummeting $0.37 per share, a 9.84% decrease, to close at $3.39 on November 5, 2024. This decline has prompted concerns among investors, leading to the investigation by Pomerantz LLP.
Pomerantz LLP, a firm specializing in corporate, securities, and antitrust class litigation, is examining whether Sana and its officers and/or directors engaged in securities fraud or other unlawful business practices. Investors who have been affected are encouraged to contact Pomerantz LLP to explore their legal options.
The investigation is ongoing, and further details will emerge as Pomerantz LLP gathers more information and evidence related to Sana Biotechnology's decisions and disclosures.
